| Song, Xianmin |
NCT02926586: Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML |
|
|
| Completed | 4 | 68 | RoW | Fludarabine, Fludara, Cytarabine, Cytosar | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia, Core-Binding Factor | 08/20 | 07/24 | | |
NCT03608059: ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center |
|
|
| Completed | 4 | 418 | RoW | ATG/PTCy, standard ATG, ATG, standard PTCy, PTCy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Myeloid Tumor | 08/23 | 08/23 | | |
NCT05379569: Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL |
|
|
| Recruiting | 4 | 142 | RoW | Fludarabine, Malilane and cyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute B Lymphoblastic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation | 11/23 | 12/25 | | |
NCT06483906: Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. |
|
|
| Recruiting | 2 | 56 | RoW | Venetoclax, Azacitidine and Homoharringtonine, VAH | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia | 07/26 | 07/28 | | |
NCT06468267: RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. |
|
|
| Recruiting | 2 | 50 | RoW | Thiotepa, fludarabine, busulfan, Cytarabine | Xianmin Song, MD | Peripheral T Cell Lymphoma | 07/26 | 07/26 | | |
NCT05576532: Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia |
|
|
| Recruiting | 2 | 30 | RoW | BCL2 Inhibitor plus IM2 regimen | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | T-lymphoblastic Lymphoma, Relapsed Disease, Refractory Lymphoma, Refractory Leukemia, Safety, Efficacy, Self | 10/24 | 10/25 | | |
NCT06686108: Demethylating Agents Combined with Venetoclax for High-risk T-Cell Lymphoma/leukemia Post-Transplant Relapse Prevention |
|
|
| Recruiting | 2 | 59 | RoW | Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse | 10/27 | 10/28 | | |
NCT05583175: Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies |
|
|
| Recruiting | 2 | 50 | RoW | Venetoclax plus RIC | Xianmin Song, MD | Leukemia, Myeloid, Acute, MDS, Hematopoietic Stem Cell Transplantation, Myeloid Malignancy | 11/24 | 11/24 | | |
NCT06754540: Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. |
|
|
| Not yet recruiting | 2 | 51 | NA | Azacitidine (AZA) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia (AML), Relapse | 01/27 | 01/27 | | |
NCT03798509: Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | Human CD19 targeted T Cells Injection | Hrain Biotechnology Co., Ltd., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | CD19-positive, Acute Lymphoblastic Leukemia | 01/22 | 01/24 | | |
NCT03919526: Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL |
|
|
| Completed | 1 | 19 | RoW | anti-CD19/CD22 CAR-T cells, Fludarabine, Cyclophosphamide | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | MRD-positive, Acute Lymphoblastic Leukemia | 11/23 | 11/23 | | |
NCT04828174: Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies |
|
|
| Suspended | 1 | 9 | RoW | anti-TRBC1 CAR-T cell therapy | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Lymphoma, Acute T Cell Leukemia, T-lymphoblastic Lymphoma | 11/23 | 11/23 | | |
NCT05290155: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies |
|
|
| Recruiting | 1 | 4 | RoW | anti-CD7 CAR-T cells | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma | 08/24 | 11/24 | | |
NCT04146207: SHR0302 and Steroid As First Line Therapy for Chronic GVHD |
|
|
| Completed | 1 | 28 | RoW | SHR0302, Prednisone | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Chronic GVHD | 09/24 | 10/24 | | |
NCT05523661: Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients |
|
|
| Recruiting | 1 | 15 | RoW | Dasatinib plus anti-CD19/CD22 CAR-T cells | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Ph Positive ALL, CAR-T Cell, Dasatinib | 03/25 | 09/25 | | |
| Recruiting | 1 | 24 | RoW | anti-CLL-1 CAR NK cells | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Relapsed Adult AML, Refractory AML | 03/26 | 03/27 | | |
NCT04078399: Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant Recurrence |
|
|
| Recruiting | N/A | 30 | RoW | Azacitidine combined with interferon preemptive treatment | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | HSCT, Efficacy and Safety | 08/22 | 08/22 | | |
NCT04126967: Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients |
|
|
| Recruiting | N/A | 100 | RoW | NGS patients | Xianmin Song, MD | NGS Monitor MRD | 12/22 | 12/23 | | |
NCT06509945: Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL |
|
|
| Recruiting | N/A | 50 | RoW | allogeneic peripheral blood stem cell transplantation | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Peripheral T Cell Lymphoma | 07/26 | 07/26 | | |
NCT06111612: Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement |
|
|
| Recruiting | N/A | 50 | RoW | | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma, Extramedullary Myeloid Tumor | 01/26 | 01/27 | | |
